Eli Lilly Pre-Tax Profit Margin 1986-2025 | LLY

Current and historical pre-tax profit margin for Eli Lilly (LLY) from 1986 to 2025. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue. Eli Lilly pre-tax profit margin for the three months ending June 30, 2025 was .
Eli Lilly Pre-Tax Profit Margin Historical Data
Date TTM Revenue TTM Pre-Tax Income Pre-Tax Margin
2025-06-30 $53.26B $16.86B 31.65%
2025-03-31 $49.00B $13.60B 27.75%
2024-12-31 $45.04B $12.68B 28.15%
2024-09-30 $40.86B $10.15B 24.84%
2024-06-30 $38.92B $8.99B 23.09%
2024-03-31 $35.93B $7.56B 21.04%
2023-12-31 $34.12B $6.56B 19.21%
2023-09-30 $32.07B $6.14B 19.15%
2023-06-30 $29.52B $7.28B 24.67%
2023-03-31 $27.69B $6.28B 22.69%
2022-12-31 $28.54B $6.81B 23.85%
2022-09-30 $29.24B $6.55B 22.40%
2022-06-30 $29.07B $6.23B 21.43%
2022-03-31 $29.32B $6.73B 22.96%
2021-12-31 $28.32B $6.16B 21.73%
2021-09-30 $27.76B $6.78B 24.44%
2021-06-30 $26.73B $6.98B 26.10%
2021-03-31 $25.49B $7.03B 27.57%
2020-12-31 $24.54B $7.23B 29.46%
2020-09-30 $23.21B $6.42B 27.67%
2020-06-30 $22.95B $6.39B 27.86%
2020-03-31 $23.09B $6.22B 26.92%
2019-12-31 $22.32B $5.27B 23.59%
2019-09-30 $21.84B $4.54B 20.76%
2019-06-30 $21.67B $4.47B 20.62%
2019-03-31 $21.62B $3.05B 14.09%
2018-12-31 $21.49B $3.68B 17.13%
2018-09-30 $19.12B $3.14B 16.43%
2018-06-30 $19.47B $2.39B 12.29%
2018-03-31 $19.71B $3.61B 18.32%
2017-12-31 $19.97B $2.31B 11.55%
2017-09-30 $22.47B $2.81B 12.49%
2017-06-30 $22.01B $3.19B 14.47%
2017-03-31 $21.59B $2.87B 13.29%
2016-12-31 $21.22B $3.38B 15.90%
2016-09-30 $20.84B $2.93B 14.05%
2016-06-30 $20.61B $3.01B 14.58%
2016-03-31 $20.18B $2.74B 13.58%
2015-12-31 $19.96B $2.79B 13.98%
2015-09-30 $19.71B $2.86B 14.51%
2015-06-30 $19.62B $2.47B 12.58%
2015-03-31 $19.58B $2.73B 13.93%
2014-12-31 $19.62B $3.00B 15.30%
2014-09-30 $20.30B $3.40B 16.73%
2014-06-30 $21.20B $4.25B 20.07%
2014-03-31 $22.20B $4.83B 21.76%
2013-12-31 $23.11B $5.89B 25.48%
2013-09-30 $23.26B $5.99B 25.76%
2013-06-30 $22.93B $6.35B 27.71%
2013-03-31 $22.60B $6.03B 26.66%
2012-12-31 $22.60B $5.41B 23.93%
2012-09-30 $22.69B $5.44B 23.96%
2012-06-30 $23.40B $5.07B 21.65%
2012-03-31 $24.05B $5.41B 22.50%
2011-12-31 $24.29B $5.35B 22.03%
2011-09-30 $24.43B $5.72B 23.41%
2011-06-30 $23.93B $5.89B 24.59%
2011-03-31 $23.43B $6.09B 26.00%
2010-12-31 $23.08B $6.53B 28.28%
2010-09-30 $22.82B $6.25B 27.40%
2010-06-30 $22.73B $5.65B 24.86%
2010-03-31 $22.28B $5.38B 24.17%
2009-12-31 $21.84B $5.36B 24.54%
2009-09-30 $21.11B $0.88B 4.19%
2009-06-30 $20.75B $-0.42B -2.02%
2009-03-31 $20.61B $-0.68B -3.30%
2008-12-31 $20.37B $-1.31B -6.42%
2008-09-30 $20.36B $3.08B 15.13%
2008-06-30 $19.74B $4.49B 22.76%
2008-03-31 $19.22B $4.21B 21.92%
2007-12-31 $18.63B $3.88B 20.80%
2007-09-30 $17.69B $3.04B 17.18%
2007-06-30 $16.97B $2.97B 17.49%
2007-03-31 $16.20B $3.08B 19.02%
2006-12-31 $15.69B $3.42B 21.79%
2006-09-30 $15.33B $4.10B 26.75%
2006-06-30 $15.06B $4.01B 26.64%
2006-03-31 $14.86B $2.83B 19.05%
2005-12-31 $14.65B $2.72B 18.56%
2005-09-30 $14.41B $2.34B 16.26%
2005-06-30 $14.09B $2.29B 16.27%
2005-03-31 $13.98B $3.27B 23.40%
2004-12-31 $13.86B $2.94B 21.23%
2004-09-30 $13.68B $3.39B 24.75%
2004-06-30 $13.54B $3.33B 24.63%
2004-03-31 $13.07B $3.38B 25.89%
2003-12-31 $12.58B $3.26B 25.93%
2003-09-30 $12.07B $3.24B 26.86%
2003-06-30 $11.72B $3.19B 27.21%
2003-03-31 $11.41B $3.15B 27.57%
2002-12-31 $11.08B $3.46B 31.22%
2002-09-30 $10.95B $3.21B 29.31%
2002-06-30 $11.04B $3.06B 27.74%
2002-03-31 $11.30B $3.28B 29.02%
2001-12-31 $11.54B $3.51B 30.37%
2001-09-30 $11.69B $3.79B 32.45%
2001-06-30 $11.63B $4.08B 35.06%
2001-03-31 $11.22B $3.87B 34.50%
2000-12-31 $10.86B $3.86B 35.53%
2000-09-30 $10.71B $3.90B 36.42%
2000-06-30 $10.48B $3.84B 36.64%
2000-03-31 $10.20B $3.73B 36.52%
1999-12-31 $10.00B $3.25B 32.45%
1999-09-30 $9.82B $2.91B 29.66%
1999-06-30 $9.81B $2.59B 26.39%
1999-03-31 $9.81B $2.50B 25.54%
1998-12-31 $9.82B $2.66B 27.13%
1998-09-30 $9.44B $2.58B 27.37%
1998-06-30 $9.03B $2.58B 28.59%
1998-03-31 $8.69B $0.64B 7.33%
1997-12-31 $8.37B $0.51B 6.09%
1997-09-30 $8.17B $0.38B 4.69%
1997-06-30 $7.82B $0.33B 4.22%
1997-03-31 $7.52B $2.08B 27.73%
1996-12-31 $7.35B $2.03B 27.65%
1996-09-30 $7.09B $1.91B 26.99%
1996-06-30 $6.91B $1.79B 25.89%
1996-03-31 $6.83B $1.76B 25.80%
1995-12-31 $6.76B $1.77B 26.11%
1995-09-30 $6.51B $1.78B 27.35%
1995-06-30 $6.39B $1.77B 27.73%
1995-03-31 $6.45B $1.80B 27.83%
1994-12-31 $6.04B $1.70B 28.13%
1994-09-30 $6.30B $0.58B 9.28%
1994-06-30 $6.32B $0.58B 9.10%
1994-03-31 $6.20B $0.61B 9.77%
1993-12-31 $6.45B $0.70B 10.89%
1993-09-30 $6.31B $1.89B 29.89%
1993-06-30 $6.25B $1.08B 17.29%
1993-03-31 $6.17B $1.08B 17.44%
1992-12-31 $6.17B $1.18B 19.18%
1992-09-30 $6.09B $1.18B 19.46%
1992-06-30 $5.95B $2.00B 33.54%
1992-03-31 $5.85B $1.96B 33.56%
1991-12-31 $5.73B $1.88B 32.83%
1991-09-30 $5.60B $1.80B 32.09%
1991-06-30 $5.54B $1.74B 31.33%
1991-03-31 $5.39B $1.67B 31.00%
1990-12-31 $5.19B $1.60B 30.78%
1990-09-30 $4.53B $1.53B 33.78%
1990-06-30 $4.30B $1.47B 34.23%
1990-03-31 $4.19B $1.40B 33.35%
1989-12-31 $4.18B $1.33B 31.87%
1989-09-30 $3.97B $1.26B 31.77%
1989-06-30 $3.87B $1.21B 31.26%
1989-03-31 $3.76B $1.16B 30.74%
1988-12-31 $3.61B $1.08B 29.96%
1988-09-30 $3.64B $0.70B 19.10%
1988-06-30 $3.66B $0.67B 18.30%
1988-03-31 $3.66B $0.63B 17.20%
1987-12-31 $3.65B $0.59B 16.30%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $495.141B $28.541B
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $450.090B 16.68
Novo Nordisk (NVO) Denmark $424.453B 49.78
Merck (MRK) United States $270.018B 37.87
AbbVie (ABBV) United States $264.086B 11.85
AstraZeneca (AZN) United Kingdom $218.471B 19.74
Novartis AG (NVS) Switzerland $218.425B 15.54
Pfizer (PFE) United States $201.199B 7.39
Sanofi (SNY) $132.955B 11.89
Innoviva (INVA) United States $0.953B 10.12